Your computer can help scientists search for new childhood cancer treatments

IBMMedical researchers and IBM (NYSE: IBM) are asking the public's help in finding prospective treatments for childhood cancers, the top worldwide cause of death by disease for children. Scientists are searching for chemical drug candidates that can affect the key molecules and proteins that control cancer cells in several common childhood cancers. However, finding drug candidates is an expensive and slow process.

To accelerate the process and broaden the search, IBM is providing those scientists free access to World Community Grid, an IBM-funded and managed program which advances scientific research by harnessing computing power "donated" by volunteers around the globe. This resource is the equivalent of a free, virtual supercomputer that enables scientists to more quickly conduct millions of virtual experiments to help pinpoint promising drug candidates for further study.

The project was announced in the United States at a press conference led by Connecticut Governor Dannel Malloy, IBM, and Dr. Ching Lau of Connecticut Children’s Medical Center, Jackson Laboratory and UConn School of Medicine, who is spearheading this crowdsourced research effort in the US.

Volunteers don't provide any time, money or technical expertise to assist with this research effort, called Smash Childhood Cancer. Instead, they participate in World Community Grid by downloading and installing a free, secure app on their computer or Android devices. While otherwise idle, volunteers' devices automatically perform virtual experiments on behalf of the research team. The results are transmitted back to researchers, where they are analyzed.

Smash Childhood Cancer brings together an international team of expert researchers from Chiba University and Kyoto University in Japan; The University of Hong Kong in Hong Kong; and the Connecticut Children's Medical Center, the Jackson Laboratory, and the University of Connecticut School of Medicine in the United States.

The global initiative is led by Dr. Akira Nakagawara, an internationally renowned pediatric oncologist, molecular biologist and CEO of the Saga Medical Center KOSEIKAN, in Japan. Dr. Nakagawara used the same research approach on a previous World Community Grid project which successfully identified drug candidates for neuroblastoma, one of the most common cancers in children.

Smash Childhood Cancer expands the search for treatments for neuroblastoma, as well as other forms of childhood cancers including brain tumor, Wilms’ tumor (tumor of the kidney), germ cell tumors (which impact the reproductive and central nervous system), hepatoblastoma (cancer of the liver) and osteosarcoma (cancer of the bone).

Since 2004, IBM’s award-winning World Community Grid has provided this resource for 27 research projects in critical areas including cancer, HIV/AIDS, Zika and Ebola viruses, genetic mapping, sustainable energy, clean water, and ecosystem preservation.

To date, World Community Grid has connected researchers to half a billion U.S. dollars' worth of free supercomputing power. This resource to accelerate scientific discovery, partially hosted in IBM's cloud, has been fueled by 720,000 individuals and 440 institutions from 80 countries who have have donated more than 1 million years of computing time on over 3 million desktops, laptops and Android mobile devices. Their participation has helped identify potential treatments for childhood cancer, more efficient solar cells, and more efficient water filtration materials.

World Community Grid is enabled by Berkeley Open Infrastructure for Network Computing (BOINC), an open source software platform developed at the University of California, Berkeley.

Join World Community Grid today to enable your computer or Android device to help Smash Childhood Cancer.

For further information, please visit:
https://www.worldcommunitygrid.org

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Human antibody for Zika virus promising for treatm…

Researchers have determined the structure of a human antibody bound to the Zika virus, revealing details about how the antibody interferes with the infection mechanism - ...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]